dc.date.accessioned | 2023-01-27T18:00:30Z | |
dc.date.available | 2023-01-27T18:00:30Z | |
dc.date.created | 2022-11-16T10:38:50Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Kline, Cassie Jain, Payal Kilburn, Lindsay Bonner, Erin R. Gupta, Nalin Crawford, John R. Banerjee, Anu Packer, Roger J. Villanueva-Meyer, Javier Luks, Tracy Zhang, Yalan Kambhampati, Madhuri Zhang, Jie Yadavilli, Sridevi Zhang, Bo Gaonkar, Krutika S. Rokita, Jo Lynne Kraya, Adam Kuhn, John Liang, Winnie Byron, Sara Berens, Michael Molinaro, Annette Prados, Michael Resnick, Adam Waszak, Sebastian Martin Nazarian, Javad Mueller, Sabine . Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. Clinical Cancer Research. 2022, 28(18), 3965-3978 | |
dc.identifier.uri | http://hdl.handle.net/10852/99343 | |
dc.description.abstract | Abstract
Purpose:
PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG).
Patients and Methods:
Patients (3–25 years) were enrolled on the basis of imaging consistent with DIPG. Biopsy tissue was collected for whole-exome and mRNA sequencing. After radiotherapy (RT), patients were assigned up to four FDA-approved drugs based on molecular tumor board recommendations. H3K27M-mutant circulating tumor DNA (ctDNA) was longitudinally measured. Tumor tissue and matched primary cell lines were characterized using whole-genome sequencing and DNA methylation profiling. When applicable, results were verified in an independent cohort from the Children's Brain Tumor Network (CBTN).
Results:
Of 38 patients enrolled, 28 patients (median 6 years, 10 females) were reviewed by the molecular tumor board. Of those, 19 followed treatment recommendations. Median overall survival (OS) was 13.1 months [95% confidence interval (CI), 11.2–18.4] with no difference between patients who followed recommendations and those who did not. H3K27M-mutant ctDNA was detected at baseline in 60% of cases tested and associated with response to RT and survival. Eleven cell lines were established, showing 100% fidelity of key somatic driver gene alterations in the primary tumor. In H3K27-altered DIPGs, TP53 mutations were associated with worse OS (TP53mut 11.1 mo; 95% CI, 8.7–14; TP53wt 13.3 mo; 95% CI, 11.8–NA; P = 3.4e−2), genome instability (P = 3.1e−3), and RT resistance (P = 6.4e−4). The CBTN cohort confirmed an association between TP53 mutation status, genome instability, and clinical outcome.
Conclusions:
Upfront treatment-naïve biopsy provides insight into clinically relevant molecular alterations and prognostic biomarkers for H3K27-altered DIPGs. | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003 | |
dc.title.alternative | ENEngelskEnglishUpfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003 | |
dc.type | Journal article | |
dc.creator.author | Kline, Cassie | |
dc.creator.author | Jain, Payal | |
dc.creator.author | Kilburn, Lindsay | |
dc.creator.author | Bonner, Erin R. | |
dc.creator.author | Gupta, Nalin | |
dc.creator.author | Crawford, John R. | |
dc.creator.author | Banerjee, Anu | |
dc.creator.author | Packer, Roger J. | |
dc.creator.author | Villanueva-Meyer, Javier | |
dc.creator.author | Luks, Tracy | |
dc.creator.author | Zhang, Yalan | |
dc.creator.author | Kambhampati, Madhuri | |
dc.creator.author | Zhang, Jie | |
dc.creator.author | Yadavilli, Sridevi | |
dc.creator.author | Zhang, Bo | |
dc.creator.author | Gaonkar, Krutika S. | |
dc.creator.author | Rokita, Jo Lynne | |
dc.creator.author | Kraya, Adam | |
dc.creator.author | Kuhn, John | |
dc.creator.author | Liang, Winnie | |
dc.creator.author | Byron, Sara | |
dc.creator.author | Berens, Michael | |
dc.creator.author | Molinaro, Annette | |
dc.creator.author | Prados, Michael | |
dc.creator.author | Resnick, Adam | |
dc.creator.author | Waszak, Sebastian Martin | |
dc.creator.author | Nazarian, Javad | |
dc.creator.author | Mueller, Sabine | |
cristin.unitcode | 185,57,20,0 | |
cristin.unitname | Sebastian Waszak Group - Computational Oncology | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.cristin | 2074694 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical Cancer Research&rft.volume=28&rft.spage=3965&rft.date=2022 | |
dc.identifier.jtitle | Clinical Cancer Research | |
dc.identifier.volume | 28 | |
dc.identifier.issue | 18 | |
dc.identifier.startpage | 3965 | |
dc.identifier.endpage | 3978 | |
dc.identifier.doi | https://doi.org/10.1158/1078-0432.CCR-22-0803 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1078-0432 | |
dc.type.version | PublishedVersion | |
dc.relation.project | NFR/187615 | |